Annovis Bio discussed p-tau217 use with the FDA and plans to submit an NDA for review.
2 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Annovis Bio discussed p-tau217 use with the FDA and plans to submit an NDA for review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA has cleared two P-tau217 blood tests for use and is collaborating on blood-based biomarker test development.
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- FDA and Pfizer are seeking regulatory approval for their products.